US Pharma MarketingBristol Myers details Krazati confirmatory study failure in colorectal cancer
The dual failure in progression-free survival and overall survival likely puts Krazati’s approval in colorectal cancer at risk. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies…
While Americans geared up for the July 4 holiday, Bristol Myers Squibb laid out how a confirmatory trial for its drug Krazati failed in colorectal cancer.
Patients taking Krazati plus another drug, the EGFR inhibitor ...
Source: Endpoints News